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Abstract
Background
Point of care tests (POCTs) are increasingly being promoted for guiding the primary medical
care of community acquired lower respiratory tract infections (CA-LRTI). POCT develop-
ment has seldom been guided by explicitly identified clinical need and requirements of the
intended users. Approaches for identifying POCT priorities and developing target product
profiles (TPPs) for POCTs in primary medical care are not well developed, and there is no
published TPP for a CA-LRTI POCT aimed at developed countries.
Methods
We conducted workshops with expert stakeholders and a survey with primary care clinicians
to produce a target product profile (TPP) to guide the development of a clinically relevant
and technologically feasible POCT for CA-LRTI.
Results
Participants with clinical, academic, industrial, technological and basic scientific back-
grounds contributed to four expert workshops, and 45 practicing primary care clinicians
responded to an online survey and prioritised community-acquired pneumonia (CAP) as the
CA-LRTI where a new POCT was most urgently needed. Consensus was reached on a
TPP document that included information on the intended niche in the clinical pathway in pri-
mary medical care; diagnostic product specification (intended use statement and test con-
cept), and minimum and ideal user specifications. Clinicians minimum requirements of a
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CA-LRTI POCT included the use of minimally invasive samples, a result in less than 30 min-
utes, no more than a single preparation step, minimum operational requirements, and detec-
tion of common respiratory pathogens and their resistance to commonly prescribed
antibiotics.
Conclusions
This multidisciplinary, multistage partnership approach generated a clinically-driven TPP for
guiding the development of a new POCT, and this approach as well as the TPP itself may
be useful to others developing a new POCT.
Introduction
A primary care point of care test (POCT) is a test carried out near to the patient that gener-
ates a result without reference to a laboratory, and rapidly enough to affect patient manage-
ment at the point of care [1, 2]. POCT development has often been driven by technological
innovation rather than in response to a clearly defined unmet clinical need, and as a conse-
quence many POCTS have not been taken up into routine clinical care. There are also some
clinical niches where POCTs are urgently required. For example, there is a need for
improved POCTs to help primary care clinicians to safely reduce and better target antibiotic
prescribing for common infections such as community acquired lower respiratory tract
infections (CA-LRTIs) [3], [4]. CA-LRTIs are one of the leading acute reasons for consulting
in primary care, and 20%-95% of patients are prescribed an antibiotic [5], [6]. More than
80% of these antibiotics may be unnecessary as CA-LRTIs in developed countries are largely
self-limiting and the majority of patients do not benefit meaningfully from antibiotic treat-
ment [7], [8], [9]. A rapid POCT that is feasible for use in primary care consultations that
helps clinicians decide when antibiotics can safely be withheld, or when antibiotic treatment
is likely to benefit patients, could improve care of this common and important condition and
help combat antibiotic resistance.
A critical factor in successful POCT development is gaining an in-depth understanding of
the end users’ (e.g. clinicians) priorities, needs and operational requirements for any new
POCT at the outset [10], [11]. This information, summarised in a target product profile
(TPP), should guide test development so that it matches clinical need and safely improves
outcomes in priority conditions. [12]. TPPs for diagnosing infections disease have been
developed by the World Health Organisation (WHO), Foundation for Innovative New Diag-
nostics (FIND) and Me´decines sans Frontie´res (MSF) [13] [14] [15] and others through the
identification of stakeholders for consultation, priority setting to identify the highest priority
for test development, defining operational and technical test characteristics, discussing dis-
puted criteria, and obtaining final consensus [16, 17]. To formalise TTP’s and ensure their
verification (consistency and completeness) formal modelling approaches have also been
helpful [18] [19]. However, as yet, there is no consensus on the priority CA-LRTI where a
POCT is most urgently needed, the ideal process for developing a POCT TPP, and there is
no published TPP for a CA-LRTI for use in developed countries. Our experience of develop-
ing a TPP for the exemplar condition of CA-LRTI illustrates how a TPP can be generated to
inform the development of a new POCT.
Developing a target product profile for a community-acquired lower respiratory tract infection point of care test
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Materials and methods
Ethics
This study was reviewed and approved by the Cardiff University School of Medicine Ethics
Committee (SMREC Reference Number 11/32).
Study design
The development of our CA-LRTI TPP was an iterative process that included meetings with
expert stakeholders from the EU Innovative Medicines Initiative (IMI) supported project,
‘RAPP-ID: Rapid Point-of-Care Test for Infectious Diseases’ (IMI RAPP-ID) project consortium
(https://www.imi.europa.eu/content/rapp-id) and a web-based survey targeted at practicing
primary care clinicians with an interest in CA-LRTI. Both qualitative and quantitative data
informed the TPP.
RAPP-ID consortium expert meetings and workshops
Four 2–3 day RAPP-ID stakeholder meetings, including breakout workshops targeted to the
specific disease areas, were conducted between April 2011 and January 2012 (see Table 1 for
meeting objectives). Stakeholders included expert and practicing clinicians, microbiologists,
scientists (molecular microbiology, chemistry and physics), diagnostic market experts and test
developers from academia and industry (European Federation of Pharmaceutical Industries
and Associations (EFPIA)) in Europe. Learning points from the TRANS-Atlantic Task Force
on Antimicrobial Resistance (TATFAR) meeting on ‘Challenges and solutions in the develop-
ment of new diagnostic tests to combat antimicrobial resistance’ informed stakeholder
discussions.
User survey for CA-LRTI POCT
An on-line survey, informed by the stakeholder meeting outputs, was developed in collabora-
tion with RAPP-ID consortium members to ensure questions covered information required
by the test developers. The survey was piloted prior to distribution. Data collection was from
12th September to 12th December 2011. The survey was aimed at practicing primary care clini-
cians with an interest in respiratory tract infections and was disseminated through RAPP-ID
Table 1. Objectives of the stakeholder planning meetings.
No Objective
1 Familiarise all stakeholders with the expertise and technologies available within the consortium
2 Discuss potential benefits of optimised disease diagnosis
3 Reach agreement on target conditions that would most benefit from improved diagnosis for adequate
antimicrobial treatment
4 Consider the clinical complexity of antibiotic treatment decisions
5 Clarify the current state of the art in diagnostic tools for each disease condition
6 Reach agreement on micro-organisms, biomarkers and thresholds (e.g. limit of detection, colonisation vs.
infection)
7 Discuss the availability and challenges of clinical sample availability, collection and processing
8 Develop models of therapeutic algorithms and patient stratification including POCT integration
9 Discuss potential scenarios from sample collection to read-out
10 Develop the user survey and discussing the technical feasibility of including the identified ideal user
requirements
https://doi.org/10.1371/journal.pone.0200531.t001
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partners, the General Practice Respiratory Infections Network (GRIN), and flyers at the Euro-
pean Respiratory Society Annual meeting (Netherlands, September 2011).
The survey had four parts (Fig 1). Part 1 aimed to identify the priority clinical LRTI sub-
conditions that clinician’s considered would most benefit from improved rapid diagnostics.
Clinical case definitions for each LRTI sub-type were included (S1 Table). Part 2 asked about
clinician’s ideal and minimum user specifications for a CA-LRTI POCT. Parts 3 and 4 asked
about clinician’s current POCT use and barriers to implementing POCT ‘s in routine care and
microbiologists.
Questions to identify clinical priority or need for the POCT asked respondents to i) select
their ideal requirement and ii) and assign a number of 1 to 5 (1-highest priority to 5-lowest
priority) for their the requirement they considered most essential. To determine the POCT
technical specifications, respondents were asked to i) select their ideal requirement and mini-
mally acceptable requirement, and ii) select yes/no for questions asking if they would consider
using a test with the listed characteristics. For all questions respondents could select more than
one option and provide free text comments. Options for ‘unsure’ and ‘not relevant to my prac-
tice’ were included.
The results of the user survey were presented to all RAPP-ID partners and the technical fea-
sibility of including the ideal user requirements into a POCT discussed with guidance from the
expert clinicians
Survey data analysis
Survey results were combined for all countries to inform the TPP. Questions asking respon-
dents to select their ideal requirements and responses to binary (yes/no) questions were ana-
lysed as number and proportion as an average. For ranking questions, the majority of
respondents selected and scored more than one priority for each question. These results were
therefore also analysed as numbers and proportions as an average. Free text comments were
included in the appendix of the TTP.
Target product profile (TPP) document
Information from the stakeholder meetings and the user survey were used to design and
inform the TPP (Table 2). Stakeholder discussions aimed to reach consensus on the final TPP
including the specifications for a CA-LRTI POCT and a proof of concept POCT.
Results
Clinician survey
Survey respondents. 45 primary care clinicians completed the survey but not all respon-
dents completed all survey questions. The majority of the respondents (21) were from the UK,
and others from Belgium (9), The Netherlands (3), Poland (3), Spain (2), USA (2), Germany
(1), Finland (1), Norway (1), Sweden (1) and Australia (1). 34 (70%) respondents were clini-
cally research active, and their clinical workload relating to infections varied from <20% to
60%.
Clinical priority for POCT development. Community acquired pneumonia (CAP) was
the LRTI given the highest overall ranking with 16 (35.6%) respondents giving it a ranking of 1
(high priority) and 34 (75.6%) giving a ranking of between 1 and 3. 11 (24.4%) respondents
also selected influenza and acute exacerbations of chronic obstructive airways disease
(aeCOPD) as their highest priority. Acute exacerbations of asthma and bronchitis were
selected as the top priority by 7 (15.6%) and 4 (8.9%) respondents.
Developing a target product profile for a community-acquired lower respiratory tract infection point of care test
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There were 88 free text responses (S2 Table).
Ideal and minimum CA-LRTI POCT requirements. For the majority of questions,
respondents selected and ranked more than one option (Table 3).
Technical and operational requirement specifications of the POCT. Questions asked
respondents to i) select their ideal requirements for POCTs, and ii) select the specifications
that would prevent them considering a POCT (Table 4), and were invited to provide free-text
comments (S3 Table).
Current use of POCTs. 21/36 of respondents (58.3%) did not use any POCT for manag-
ing respiratory infections, 7 (19.4%) used a CRP test and five (13.9%) a ‘Strep A’ test. When
suspecting a false positive POCT result, 22 (64.7%) respondents would follow-up the patient,
and 16 (47.1%) would re-test; 21 (63.6%) would follow-up the patient; 16 (48.5%) would re-
test; 11 (33.3%) would use clinical algorithms, and; 10 (27.8%) would refer samples to a labora-
tory or conduct additional tests. In relation to a question on laboratory results, 8 (24.2%)
respondents indicated that they would ignore laboratory results if they suspected a false nega-
tive and 7 (21.2%) would prescribe a broad-spectrum antibiotic.
Clinician’s perceived barriers to the uptake of a new POCT. 29 respondents provided
free-text comments (S4 Table). Speed and cost of the test were most frequently perceived
Fig 1. Survey to identify clinical need, minimum and ideal user requirements and perceived barriers for a new
CA-LRTI POCT.
https://doi.org/10.1371/journal.pone.0200531.g001
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barrier (n = 19 (65.5%)). Other barriers related to test cost versus clinical benefit (n = 5
(17.3%)); test complexity and training (n = 19 (65.5%)); time and workload (n = 10 (34.5%));
performance, accuracy and reliability (n = 7 (24.1%)), and patient acceptability (n = 3
(10.3%)).
The target product profile (TPP) document. Consensus on a final TPP to guide the
CA-LRTI POCT development included the primary care clinician’s top priority and ideal and
their minimum test performance requirements. The TPP document also included the POCT
diagnostic product specification statement, a description of the test concept and a proposed
proof of concept evaluation (Table 5). The test concept provides a detailed description of the
desired POCT. The proof of concept test describes the test and methods to demonstrate, in
principle, the feasibility of developing a POCT that matches the TPP. Details of the clinical
pathway were also included to promote understanding of the test setting for all the project
stakeholders. Examples of currently available tests and emerging technologies, the current
market and regulatory pathway for POCT development were also reviewed and included as
summary information in the TPP document. The TPP document is available as supplementary
material (S1 File)
Discussion
We have described an approach for ensuring that that the development of a new diagnostic is
driven by clinical need and the requirements of the clinical end users. Critical steps to identify
gaps and needs for a new POCT included multidisciplinary stakeholder meetings that gener-
ated critically useful information and informed a survey of clinicians, both of which identified
clinical priorities and the minimum and ideal performance characteristics of a new POCT.
Table 2. Structure of the target product profile (TPP) document.
SECTIONS CONTENTS
Front of document Authorizations, appendix, glossary, definitions
Aim of document Reference document for researchers, developers and manufacturers
Source of document
information
Workshops, surveys, literature reviews
Clinical need and requirement
for new test
Include clinical setting, fit into clinical pathway, POCT concept diagram,
overview of current tests used in clinical practice
Information on clinical samples Sample type, nature of samples and target molecules (e.g. biomarkers,
pathogens), sampling equipment, acceptability of samples
Diagnostic product
specification
Intended use statement, descriptions of test concept (description of the desired
test) and proof of concept (test and methods that will demonstrate in principle
the feasibility of developing a test with the desired TPP)
TEST SPECIFICATIONS
(Tables of key features including both (ideal (target) and minimum (acceptable) requirements).
Technical specifications: Intended use, clinical decision to be influenced, place of use, patient criteria,
target molecule, performance against reference, type of analysis, readout system,
sample type, reproducibility, compliance with regulators, reproducibility near
clinical thresholds.
Operational characteristics: Sample requirements (e.g. volume of sample, sample preparation, quality,
requirement for precise volumes), controls, waste disposal, batching, end-user
profile, training, biosafety, test speed, test stability, storage requirements, shelf
life, lifetime of machine, need for additional equipment, cost.
Market overview Cost of manufacturing single device, competitive landscape, regulatory pathway,
competitive landscape, region of commercialization, market segmentation
Information on Competitor
Tests
Available and those coming to market. Details on test performance,
characteristics, market uptake etc.
https://doi.org/10.1371/journal.pone.0200531.t002
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Table 3. The gaps and needs for a priority CA-LRTI POCT as defined by an expert consensus process with primary care clinicians.
Question (number of respondents
completing question on ideal and
minimum specification)
Answer Options Ideal specification (number (%) selecting as top
priority)
Minimum specification
(number (%) selecting as
top priority)
How would a new CA-LRTI
POCT best guide treatment
decisions? (41)
1. Treatment monitoring; Initial
treatment targeting (prescribing
optimal and appropriate antibiotic)
2. De-escalation of treatment from
earlier more powerful (broad-
spectrum) to less powerful
appropriate antibiotic
Initial treatment targeting (40, (97.6)) Initial treatment targeting
(34 (82.9))
What patient sub-group should
the test benefit? (38)
1. Neonates;
2. Children;
3. Adults <65 years;
4. Adults 65–80 years;
5. Adults >80 years
Adults aged 65–80 years (25 (65.8)) Adults aged 65–80 years (19
(48.7))
Antibiotic status of patients for
testing? (41)
1. Antibiotic pre-treated;
2. Antibiotic naïve (no previous
antibiotic treatment for that episode)
3. All patients
All patients including antibiotic pre-treated and
antibiotic naïve patients (17 (41.5))
Antibiotic naïve (25 (65.8))
What category of staff would use
the test most often? (40)
1. Doctors
2. Nurses
3. Practice nurse
4. Nurse practitioner
Doctors (33 (82.5)) Doctors (29 (70.7))
What aetiological agents do you
think are most important for the
test to detect? (42)
1. Bacteria
2. Viruses
Bacteria (36 (85.7)) Not Available (NA)
Which do you think are the most
important bacteria for the test to
detect? (35)
1. List of common respiratory pathogens
2. Other
3. Unsure
S. pneumoniae (26 (74.3)); H. influenzae (21 (60.0)); M.
pneumoniae (17 (48.6)); Unsure (8 (22.9)).
NA
What level of bacterial
identification is required? (34 and
19)
1. Gram-positive / Gram-negative
2. Genus level (e.g. Streptococcus spp)
3. Species level (e.g. S. pneumoniae)
4. Genus level and quantification
5. Species level and quantification
6. Unsure
4&5) and e.g. for de-escalation of
treatment or colonisation vs. infection
Gram-positive / Gram-negative (9 (26.5)); Species level
(8 (23.5)); Unsure (13 (38)).
Gram-positive / Gram-
negative (8(50))
Would information about
antibiotic resistance change your
clinical practice? (40)
1. Yes
2. No
Yes (39 (97.5)) NA
What resistance do you think the
test should detect? (36)
1. List of antibiotics (including generic
names and groups);
2. Other
Penicillin’s (25 (69.4)); Macrolides (17 (47.2));
Amoxicillin-Clavulanate (16 (44.4)); Beta-lactamases
(14 (38.9)); Fluoroquinolones (14 (38.9));
Cephalosporins (13 (36.1))
NA
Level of antibiotic susceptibility
information required? (38 and 21)
1. Resistance gene absent;
2. Resistance gene present;
3. Sensitive/resistant corresponding to
antibiotic breakpoint;
4. Unsure
Sensitive/resistant corresponding to antibiotic
breakpoints (24 (63.2)); Unsure (13 (34))
Sensitive/resistant
corresponding to antibiotic
breakpoints (17 (81))
Which do you think are the most
important viruses for the test to
detect? (11)
1. List of common respiratory viruses;
2. Other;
3. Unsure
Influenza (10 (90.9)); Respiratory syncytial virus (6
(54.5)); Para-influenza and adenoviruses (4 (36.4))
NA
(Continued)
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Nine months was allocated for the initial planning stage of the RAPP-ID project, including
the development of the TPP. This included workshops to ensure a shared understanding and
vision was reached between multidisciplinary stakeholders. Scientists and technologists were
introduced to the clinical need, the nature of the clinical setting, the clinical samples that could
be obtained, the potential pathogens and challenges of establishing minimally acceptable per-
formance thresholds. Clinicians gained an understanding of the available broad approaches,
technologies and manufacturing restrictions. Involving all stakeholders in the design of the cli-
nician survey and the TPP ensured that all information required by the technologists, test
developers and manufacturers was captured.
Community acquired pneumonia was the clinical priority for POCT development. Clini-
cians minimum requirements for a CA-LRTI POCT included; that the test can be performed
by doctors, uses minimally invasive samples, gives a result that is easy to interpret in less than
30 minutes, requires no more than a single preparation step, has minimum operational
requirements, and can detect common respiratory pathogens and resistance to antibiotics
commonly prescribed in primary care.
Comparison with existing literature
Previous studies have described methods for consulting target users in the early development
of new diagnostics, and have identified product failures arising from a disconnect between
technology developers and the end users [11], [20] [21], [22]. Perceived barriers to involving
actual users in the design and development process include lack of time and requirements for
ethical approval [23].
Table 3. (Continued)
Question (number of respondents
completing question on ideal and
minimum specification)
Answer Options Ideal specification (number (%) selecting as top
priority)
Minimum specification
(number (%) selecting as
top priority)
Level of viral identification
required? (12 and 9)
1. Species identification;
2. Species and strain identification;
3. Species and viral load;
4. Flu A/B discrimination;
5. Unsure
Species level identification (6 (50)); Unsure (4 (33.3)) Species level identification
(5 (55.6))
Would information about
antiviral resistance change your
clinical practice? (39)
1. Yes;
2. No
Yes 25 (64.1)) NA
Most important antiviral
resistance to detect? (14 and 8)
1. List of antivirals;
2. Other;
3. Unsure
Oseltamivir (Tamiflu) (8 (57.1)); Unsure (4(28.6)) Oseltamivir (7 987.5))
Which test prediction is
important to you? (36 and 30)
1. Rate of true positives
2. Rate of true negatives
3. Rate of false positives
4. Rate of false negatives
5. Unsure
Rate of true positives (20 (55.6)); Rate of true negatives
(16 (44.4)); Unsure (5 (13.9))
Rate of true negatives (18
(62.1))
Total time taken from taking
patient sample to receiving test
result? (35 and 31)
1. <30 minutes
2. <1 hour
3. 1–2 hours
4. 2–4 hors
5. >6 hours
6. Other
<30 minutes (30 (85.7)) <30 minutes (22 (81.5))
https://doi.org/10.1371/journal.pone.0200531.t003
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Projects to develop new POCTs are complex and require multi-disciplinary collaborations
with partners that have a wide range of expertise [24].
A number of TPPs have been developed for managing infectious diseases in resource-lim-
ited settings and these have focussed on detection of the infecting agent or differentiating
between bacterial and non-bacterial infections to reduce antimicrobial overuse [13, 14, 17, 25,
26]. Clinicians’ views of POCTs for common infections including LRTI have been established
in other studies [10], [27], [28], [29]. However, we were not able to identify any published
Table 4. Clinicians’ technical and operational requirements, and specifications preventing test use.
TECNHICAL/OPERATIONAL
FEATURE
CLINICIANS IDEAL REQUIREMENTS
(number of respondents selecting as top priority (percentage))
SPECIFICATION THAT WOULD PREVENT
CONSIDERATION OF A POCT
(number of respondents (percentage))
Acceptable clinical samples • Throat swabs (28 (77.8));
• Urine, nasal swabs, sputum, capillary blood and exhaled breath (20
(>55));
• 31 (88.6) of respondents would consider a test that required a breath
sample
• Faecal samples (31 (88.66))
• Induced sputum (27 (84.4))
• Venous blood (11 (31.4))
Sample preparation
procedures
• The ability to use approximate volumes and a single preparation step (26
(74.3));
• Not prone to contamination and no safety containment issues (25 (75.3)
and 21 (61.8))
• Requires >3 preparation steps (27 (84.4));
• Requires >2 preparation steps (19 (59.4);
• Highly sensitive to contamination (22 (66.7))
Storage of test and reagents • Stability at room temperature (36 (100));
• Minimum shelf life of 12 months (23 (63.9))
• Shelf life of less than 6 months (17 (50));
• Unstable at room temperature (11 (32.4));
Test kit requirements • Totally self-contained kit (30 (85.7));
• No calibration required (20 (57.1));
• Needs to contain the specimen collection device (15 (42.9))
• Requires calibration before each test (19 (59.4));
• Does not contain the specimen collection device
(15 (45.5));
• Kit not totally self-contained (13 (37.1))
Control requirements • All controls must be included as part of the kit (26 (74.3));
• No need for external quality control (22 (62.9));
• Needs to include controls within the kit (12 (34.3));
• External quality control needed 18 (54.5));
• Kit does not include controls (18 (52.9));
• Kit does not include controls as part of each test (15
(48.4))
Instrumentation requirements • The instrument must be robust (24 (66.7));
• No maintenance required, fits into a small area, and hand-held (> 21
(61.8%)) for each specification)
• Requires separate containment area (27 (77.1%));
• Requires monthly maintenance (24 (68.6%));
• Fragile (22 (62.9))
Test result requirements • Easy to read (31 (86.1));
• Connectivity enabling downloading of results to patient records (25
(69.4));
• Unambiguous results, a simple yes/no/invalid readout and readable for at
least an hour (>20 61.8%) for each specification)
• Ambiguous results (28 (82.4));
• Complex to read (22 (62.9));
• Does not allow automatic download to patient
record (4 (11.8)).
Acceptable training
requirements?
• Test can be performed by any healthcare worker without training (24
(70.6);
• Training time of one day maximum (22 (64.7));
• Self-administration by patients (11 (32.4))
• Requires more than one day training (25 (71.4));
• Can only be performed by an experience healthcare
worker (11 (31.4))
Power requirement • Powered by battery (30 (88.2));
• Standard mains (27 (79.4))
• Could not be powered by standard mains (7 (20.6));
• Could not be powered by battery (4 (11.8))
Acceptable maximum cost per
patient test
• No more than €10 (25 (73.5));
• No more than €20 (11 (32.4)
NA
Acceptable maximum
instrumentation cost
• <€1,000 (20 (58.8));
• €5,000 (9 (26.5));
• No cost (14 (41.2))
NA
https://doi.org/10.1371/journal.pone.0200531.t004
Developing a target product profile for a community-acquired lower respiratory tract infection point of care test
PLOS ONE | https://doi.org/10.1371/journal.pone.0200531 August 1, 2018 9 / 13
TPPs for a primary care CA-LRTI POCT in developed countries or studies that identify which
particular CA-LRTI condition would most benefit from a new POCT.
While our study identified many positive reasons for developing a POCT for CA-LRTI,
some barriers were also highlighted. These included that a test focussing on aetiology may lead
to an antibiotic prescription for all bacterial infections, including those that are self-limiting,
and that in many cases, diagnosis and prognosis was obvious on clinical grounds alone.
There may be numerous current technical barriers to achieving a test to meet many of the
clinicians ‘ideal’ requirements. The ideal specifications also need to be considered in light of
the risks that they may pose to successful POCT development.
Strengths and limitations. The clinician survey was relatively small and the sample was
largely one of convenience. However, respondents were practicing primary care clinicians
with an interest in CA-LRTI. The survey instrument was relatively long which may led to
incomplete responses. The TPP was confidential and dissemination was initially limited to the
RAPP-ID consortium until the end of the project, which resulted in a delay to placing it in the
public domain. Ideally, a formal validation of the TPP would also have been conducted. To
investigate interesting relations between variables and add depth to the data analysis additional
methods such as association rule learning and data mining technology could have been used.
Conclusion
The development and consensus for a TPP ensures cross-disciplinary dialogue and shared
understanding and focuses technological innovation on meeting prospectively identified clini-
cal need. Looking ahead, a TPP should be regularly reviewed throughout product development
Table 5. The diagnostic product specification statement.
INTENDED USE(S) OF THE TEST:
• A POCT to enhance the initial clinical management of suspected CAP in adult patients presenting in primary
care. The POCT should achieve this by indicating with sufficient precision the presence or absence of the
organisms that account for almost all cases of CAP, so as to inform decisions about whether an immediate
antibiotic prescription is necessary or not.
• The primary target population is in primary care.
• The POCT should be easy to use by a range of health care professionals in a variety of settings (e.g. doctors, nurses
and any community health workers in any primary care setting doctors surgery, GP home visit, and nursing
homes).
• The POCT should be feasible and cost effective in the primary care setting.
• The test is designed to be used with either nasopharyngeal (NP) swab or exhaled breath samples without need for
prior culture.
TEST CONCEPT:
• The POCT should be able to detect Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus,
Moraxella catharralis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella spp and common viral
respiratory pathogens including rhinovirus, influenza A and B, coronaviruses, human metapneumoviruses,
respiratory syncytial virus (RSV), and parainfluenza.
• The POCT should be able to detect penicillin and macrolide resistance in common potentially pathogenic
respiratory bacteria.
• The POCT should provide a technologically flexible platform that allows the future incorporation of biomarker
detection, should biomarkers be identified that will add to diagnostic performance.
PROOF OF CONCEPT TEST:
• A POCT to identify S. pneumoniae, H. influenzae, S. aureus, M. catharralis, C. pneumoniae, M. pneumoniae,
Legionella spp and common viral respiratory pathogens including rhinovirus, influenza A and B, coronaviruses,
human metapneumoviruses, respiratory syncytial virus (RSV), and para-influenza.
• The results of the POCT should be used to accurately identify the presence of common pathogenic respiratory
bacteria and viruses in adult patients presenting with symptoms of CA-LRTI, to rapidly guide clinicians in their
decisions whether or not to prescribe antibiotic or antiviral treatment.
https://doi.org/10.1371/journal.pone.0200531.t005
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to take into the account any changing clinical priorities, emerging technologies, and barriers
that were unforeseen during development and evaluation stages [30].
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